Penelope (Penny) Markham, PhD, is Senior Vice President and leads the Liver Disease and Long COVID programs at BioVie. Penny led the development of modified terlipressin compounds for LAT Pharma LLC, the predecessor company to BioVie, for 7 years prior to its acquisition by BioVie. Prior to that, she spent 15 years in cellular immunology, infectious disease, bacteriology and drug discovery research.  Penny was a co-founder and Research Director for Influx, Inc. engaged in anti-infective drug discovery. She has been a member of NIH grant review panels and consulted for several pharmaceutical companies in a variety of therapeutic areas including Orphan drug development. Penny has more than 25 publications in peer-reviewed journals and six patents and holds a BS in Biochemistry from the University College Cork, Ireland, an MS from Strathclyde University, Scotland, and a PhD from Rush University, Chicago.